Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
Related Questions
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?
How would you respond to a patient with early stage resectable NSCLC who has a clinical complete response to neoadjuvant chemoIO who subsequently declines surgery, not feeling it's necessary anymore?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
What would be the recommended sequencing of adjuvant chemotherapy, osimertinib, and postoperative radiation for a patient with NSCLC who was upstaged to stage III following resection with negative margins?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?
